Bonkers valuations for anything remotely connected to Covid-19
The share price of a small investment group soared on news that one its portfolio companies is involved in developing a Covid-19 test, despite no indication of the financial impact and whether the test might actually be commercialised. Another software group supporting the UK healthcare sector commits to its full year dividend, a rare thing.
EMIS: continuing to invest and a dividend is paidUK leader in connected healthcare software EMIS Group (LON:EMIS) has confirmed that trading for the year to date is in line with expectations. A recent initiative in which they are involved includes a research collaboration for a trial testing the effectiveness of various treatments in the early phases of Covid-19. The balance sheet remains in good shape with cash of £40.0m at 30 April 2020, no bank debt and undrawn banking facilities of up to £60.0m. This means EMIS is one of the few companies able to commit to a final dividend…